European Commission approves DAYBU, opening a 30-market pathway for Neuren
The European Commission has granted marketing authorisation for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and paediatric patients aged five years and older. DAYBU is the first and only treatment approved for Rett syndrome in the European Union.
The approval was announced by Neuren Pharmaceuticals‘ exclusive global licensee for trofinetide, Acadia Pharmaceuticals (Nasdaq: ACAD), under the companies’ licence agreement. Neuren (ASX: NEU) is the originator of the therapy.
For investors, the near-term financial trigger is clear. Under the licence agreement, Neuren is entitled to receive US$35 million following the first commercial sale in Europe.
Trofinetide is not approved for sale in Australia.
Key details of the approval include:
- Authorised for marketing across all 27 EU member states, plus Iceland, Liechtenstein and Norway, for a total of 30 markets
- First commercial launch anticipated in Germany, early Q4 2026, according to Acadia
- Marketing authorisation announced on 25 August 2026
When big ASX news breaks, our subscribers know first
What the EU approval means for Neuren’s revenue
The licence agreement with Acadia establishes a tiered, sales-linked economic structure for Europe. Beyond the initial payment on first commercial sale, Neuren is positioned to receive escalating milestone payments and recurring royalties as commercial uptake builds across the region.
The table below summarises the Europe-specific milestone economics owed to Neuren under the Acadia licence agreement.
| Payment type | Amount / Rate | Trigger |
|---|---|---|
| First commercial sale payment | US$35 million | On first EU commercial sale |
| Sales milestone payments | Up to US$170 million | Escalating annual net sales thresholds |
| Tiered royalties | Mid-teens to low-20s % | Of net sales |
These are staged payments that scale with commercial performance across the EU. Because Acadia carries responsibility for commercialisation, Neuren will receive royalties and milestones as adoption grows.
Neuren’s royalty revenue model delivered A$65 million in income and A$30 million in profit in 2025, with the DAYBUE franchise already accumulating A$510 million in cumulative sales since its April 2023 launch, providing a financial baseline against which European milestone payments would stack.
Understanding Rett syndrome and why the EU-first approval matters
Rett syndrome is a serious neurological disorder representing an area of profound unmet medical need. Until this approval, European patients had no approved treatment for the condition.
Neuren’s therapies target the role of Insulin-like growth factor 1 (IGF-1) in the brain, a naturally occurring protein important to brain development and function. The company uses orally administered analogs of naturally occurring peptides to address neurological disorders caused by genetic abnormalities or brain injury.
As the first and only approved treatment for Rett syndrome in the EU, DAYBU is the first and only approved treatment for Rett syndrome in the EU.
CEO Commentary
“We are delighted for the Rett syndrome community in Europe, who, until now, have had no approved treatment for this devastating condition. The European Commission’s approval of DAYBU is particularly rewarding for Neuren given our long-standing commitment to developing therapies for serious neurological disorders with profound unmet need. We look forward to seeing our partner Acadia make DAYBU available for Rett patients and families in Europe,” said Jon Pilcher, Chief Executive Officer of Neuren.
A global approval footprint and the pipeline behind it
The EU approval adds to a growing global regulatory base for trofinetide across multiple jurisdictions and formulations.
Existing trofinetide approvals include:
- DAYBUE® oral solution, approved by the US Food and Drug Administration (FDA), Health Canada, and Israel’s Ministry of Health
- DAYBUE® STIX powder, approved by the FDA
- DAYBU®, now approved by the European Commission
Beyond trofinetide, Neuren is advancing a second candidate that broadens the investment case. NNZ-2591 (ercanetide) is an investigative drug candidate in clinical development across a range of neurodevelopmental disorders.
Key points on the NNZ-2591 pipeline include:
-
In clinical development as an oral solution for multiple neurodevelopmental disorders, including Phelan-McDermid, Pitt Hopkins and Angelman syndromes
-
Each programme has been granted “orphan drug” designation in the United States and the European Union, plus FDA Fast Track and Rare Pediatric Disease designations
-
Also in development for hypoxic ischemic encephalopathy (HIE), a serious condition caused by brain injury before or shortly after birth
-
A Phase 3 “Koala” trial is underway, a randomised, double-blind, placebo-controlled study in children aged 3 to 12 with Phelan-McDermid syndrome, alongside a 52-week open-label extension
What comes next for investors
The most immediate catalyst is the anticipated commercial launch in Germany, expected in early Q4 2026 according to Acadia. That first commercial sale triggers the US$35 million payment to Neuren under the licence agreement.
Beyond Germany, the broader rollout potential across the 30 approved markets provides a pathway toward the sales milestone payments of up to US$170 million and tiered royalties in the mid-teens to low-20s percentage range of net sales.
Record royalty guidance of A$70-77 million for 2026, representing 8-18% growth over 2025, was issued before the European approval was confirmed, meaning the EU commercial launch now represents incremental upside to a baseline that was already tracking at historic highs.
For investors, the approval delivers a validated, partner-commercialised lead product now positioned to generate staged European economics. That commercial foundation sits alongside a pipeline of designated-status programmes led by NNZ-2591, extending the company’s reach across multiple rare neurological disorders.
Don’t Miss the Next ASX Healthcare Winner
Big News Blast delivers FREE breaking ASX healthcare news to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers who stay ahead of market-moving announcements the moment they drop. Click the “Free Alerts” button at StockWire X to start receiving alerts today.